Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$12.62
-0.1%
$11.70
$7.43
$12.86
$28.19B0.7657,863 shs29,320 shs
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$73.40
-0.7%
$67.90
$57.65
$94.80
$33.61B1.143.45 million shs3.05 million shs
Luxottica Group SpA stock logo
LUXTY
Luxottica Group
$55.80
+0.4%
$55.80
$49.83
$69.03
$27.07B0.2714,259 shs2,900 shs
ResMed Inc. stock logo
RMD
ResMed
$251.18
-0.6%
$234.21
$179.42
$263.05
$36.83B0.781.01 million shs614,327 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
-0.10%+1.55%+3.42%+15.97%+52.97%
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
+3.14%+3.88%+5.80%-11.78%-2.45%
Luxottica Group SpA stock logo
LUXTY
Luxottica Group
0.00%0.00%0.00%0.00%0.00%
ResMed Inc. stock logo
RMD
ResMed
+0.63%+2.20%+3.05%+14.77%+19.33%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
N/AN/AN/AN/AN/AN/AN/AN/A
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
4.264 of 5 stars
3.45.01.70.02.31.72.5
Luxottica Group SpA stock logo
LUXTY
Luxottica Group
N/AN/AN/AN/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
4.0647 of 5 stars
2.31.03.34.62.31.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
3.33
BuyN/AN/A
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
2.83
Moderate Buy$88.2720.26% Upside
Luxottica Group SpA stock logo
LUXTY
Luxottica Group
0.00
N/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
2.60
Moderate Buy$259.333.25% Upside

Current Analyst Ratings Breakdown

Latest RMD, GEHC, FSNUY, and LUXTY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
ResMed Inc. stock logo
RMD
ResMed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$286.00
5/15/2025
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/6/2025
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$86.00 ➝ $78.00
5/5/2025
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Neutral$74.00 ➝ $73.00
5/1/2025
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$94.00 ➝ $82.00
5/1/2025
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$103.00 ➝ $89.00
5/1/2025
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$96.00 ➝ $85.00
4/30/2025
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$105.00 ➝ $86.00
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$274.00
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$247.00 ➝ $255.00
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$290.00 ➝ $285.00
(Data available from 6/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$24.01B1.17$1.89 per share6.68$9.52 per share1.33
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$19.80B1.70$4.60 per share15.94$18.51 per share3.97
Luxottica Group SpA stock logo
LUXTY
Luxottica Group
$10.34B2.62$3.57 per share15.62$13.74 per share4.06
ResMed Inc. stock logo
RMD
ResMed
$5.02B7.33$9.96 per share25.23$35.77 per share7.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$382.05M$0.1966.4113.71N/AN/A3.72%1.67%8/6/2025 (Estimated)
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$1.99B$4.7516.9514.123.1910.13%25.74%6.29%7/30/2025 (Estimated)
Luxottica Group SpA stock logo
LUXTY
Luxottica Group
$1.17B$2.2924.37N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$1.02B$8.9129.6524.241.5325.34%26.17%18.60%7/30/2025 (Estimated)

Latest RMD, GEHC, FSNUY, and LUXTY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$0.2170$0.23+$0.0130$0.11$5.41 billion$5.92 billion
4/30/2025Q1 2025
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$0.91$1.01+$0.10$1.23$4.66 billion$4.78 billion
4/23/2025Q3 2025
ResMed Inc. stock logo
RMD
ResMed
$2.36$2.37+$0.01$2.48$1.28 billion$1.29 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$0.181.43%N/A94.74%N/A
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$0.140.19%N/A2.95%1 Years
Luxottica Group SpA stock logo
LUXTY
Luxottica Group
$0.911.63%N/A39.74%N/A
ResMed Inc. stock logo
RMD
ResMed
$2.120.84%N/A23.79%13 Years

Latest RMD, GEHC, FSNUY, and LUXTY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.530.9%5/8/20255/8/20256/12/2025
5/22/2025
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$0.18271.48%5/27/20255/28/20256/4/2025
3/27/2025
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
quarterly$0.03500.17%4/25/20254/25/20255/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
0.57
1.36
1.05
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
0.88
1.04
0.83
Luxottica Group SpA stock logo
LUXTY
Luxottica Group
0.19
1.18
0.88
ResMed Inc. stock logo
RMD
ResMed
0.13
3.33
2.29

Institutional Ownership

CompanyInstitutional Ownership
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
N/A
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
82.06%
Luxottica Group SpA stock logo
LUXTY
Luxottica Group
0.09%
ResMed Inc. stock logo
RMD
ResMed
54.98%

Insider Ownership

CompanyInsider Ownership
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
N/A
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
0.28%
Luxottica Group SpA stock logo
LUXTY
Luxottica Group
75.00%
ResMed Inc. stock logo
RMD
ResMed
0.71%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
193,8652.23 billionN/ANot Optionable
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
50,000457.89 million456.06 millionOptionable
Luxottica Group SpA stock logo
LUXTY
Luxottica Group
82,282485.06 millionN/ANot Optionable
ResMed Inc. stock logo
RMD
ResMed
8,160146.63 million145.82 millionOptionable

Recent News About These Companies

Analysts Set ResMed Inc. (NYSE:RMD) PT at $259.33
ResMed Inc. stock logo
ResMed Inc. (NYSE:RMD) CEO Sells $2,011,940.89 in Stock
ResMed Inc Reports Change in Beneficial Ownership
ResMed: A Sleeping Giant Hiding In Plain Sight
3 Cash-Heavy Stocks with Competitive Advantages

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fresenius SE & Co. KGaA stock logo

Fresenius SE & Co. KGaA OTCMKTS:FSNUY

$12.62 -0.01 (-0.10%)
As of 06/10/2025 03:51 PM Eastern

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

GE HealthCare Technologies stock logo

GE HealthCare Technologies NASDAQ:GEHC

$73.40 -0.52 (-0.70%)
Closing price 04:00 PM Eastern
Extended Trading
$73.25 -0.15 (-0.20%)
As of 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Luxottica Group stock logo

Luxottica Group OTCMKTS:LUXTY

$55.80 +0.20 (+0.36%)
As of 03/22/2019

Luxottica Group S.p.A., together with its subsidiaries, provides fashion, luxury, sports, and performance eyewear worldwide. It operates through two segments, Manufacturing and Wholesale Distribution, and Retail Distribution. The Manufacturing and Wholesale Distribution segment engages in the design, manufacture, distribution, and marketing of proprietary and designer lines of prescription frames and sunglasses. This segment offers its products under proprietary brands, such as Ray-Ban, Oakley, Persol, Oliver Peoples, Alain Mikli, Arnette, and Vogue Eyewear; and licensed brands, including Giorgio Armani, Emporio Armani, Armani Exchange, Brooks Brothers, Burberry, Bulgari, Chanel, Coach, Dolce&Gabbana, DKNY, Michael Kors, Paul Smith Spectacles, Prada, Miu Miu, Ralph Lauren, Polo Ralph Lauren, Ralph, Starck Eyes, Tiffany & Co, Tory Burch, Valentino, Versace, and Ferrari. The Retail Distribution segment operates prescription eyewear stores primarily under its retail brands, including LensCrafters, Sunglass Hut, Pearle Vision, OPSM, Laubman & Pank, GMO, David Clulow, Salmoiraghi & Viganò, Ray-Ban, Oakley and Vault, Oliver Peoples, Alain Mikli, Ilori Optical, and Optical Shop of Aspen; and licensed brands, such as Sears Optical and Target Optical. As of December 31, 2017, it operated approximately 9,000 stores. The company was founded in 1961 and is headquartered in Milan, Italy. As of October 1, 2018, Luxottica Group S.p.A. operates as a subsidiary of EssilorLuxottica.

ResMed stock logo

ResMed NYSE:RMD

$251.18 -1.48 (-0.59%)
Closing price 03:59 PM Eastern
Extended Trading
$251.42 +0.25 (+0.10%)
As of 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.